Capstone Investment Advisors
DYN icon

Capstone Investment Advisors’s Dyne Therapeutics DYN Stock Holding History

Capstone Investment Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,217
Closed -$203K – 1723
2026
Q1 		$203K Sell
11,217
-1,483
-12% -$25.6K ﹤0.01% 1518
2025
Q4 		$248K Buy
+12,700
New +$241K ﹤0.01% 1433
2024
Q2 		– Sell
-20,248
Closed -$575K – 2180
2024
Q1 		$575K Buy
+20,248
New +$458K ﹤0.01% 1479

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capstone Investment Advisors's DYN Position: Q2 2026 in Review

Capstone Investment Advisors sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 11,217 shares — an estimated $203K sold.

Capstone Investment Advisors first reported a position in DYN in Q1 2024 and held it in 3 quarters. The position peaked at $575K in Q1 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Capstone Investment Advisors reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Capstone Investment Advisors sold 11,217 Dyne Therapeutics shares in Q2 2026, an estimated $203K.
  • Capstone Investment Advisors first reported a position in Dyne Therapeutics in Q1 2024 and held it in 3 quarters.
  • Capstone Investment Advisors's Dyne Therapeutics position peaked at $575K in Q1 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.